Skip to main content
Vivoryon's pipeline on Muck Rack

Vivoryon's pipeline

As seen in: FinanzNachrichten.de
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vivoryon's

Contact Vivoryon's, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Press Release: Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress

|
By Fraunhofer IZI, Vivoryon's pipeline, Samir Shah, Kohlberg Kravis Roberts
| FinanzNachrichten.de
Press Release: Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress -- Significantly advanced varoglutamstat EU and U.S. clinical studies, VIVIAD and VIVA-MIND, providing promising initial safety data -- Both VIVIAD and VIVA-MIND studies on track; final data from VIVIAD expected in 1Q2024 and clinical update on VIVA-MIND expected in 2H2023...
Open in Who Shared Issue with article?

Press Release: Vivoryon Therapeutics N.V. Reports -2-

|
By Fraunhofer IZI, Vivoryon's pipeline, Samir Shah, Kohlberg Kravis Roberts
| FinanzNachrichten.de
Press Release: Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress -- Significantly advanced varoglutamstat EU and U.S. clinical studies, VIVIAD and VIVA-MIND, providing promising initial safety data -- Both VIVIAD and VIVA-MIND studies on track; final data from VIVIAD expected in 1Q2024 and clinical update on VIVA-MIND expected in 2H2023...
Open in Who Shared Issue with article?

Press Release: Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress

|
By Fraunhofer IZI, Samir Shah, Kohlberg Kravis Roberts, Vivoryon's pipeline
| FinanzNachrichten.de
Press Release: Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress -- Significantly advanced varoglutamstat EU and U.S. clinical studies, VIVIAD and VIVA-MIND, providing promising initial safety data -- Both VIVIAD and VIVA-MIND studies on track; final data from VIVIAD expected in 1Q2024 and clinical update on VIVA-MIND expected in 2H2023...
Open in Who Shared Issue with article?
See all 3 articles